Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff Settleman

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Cell Cycle (Georgetown, Tex.)|July 1, 2016
TORquing metabolic reprogramming in cancer cellsRaju Pusapati, Jeff Settleman
Nature Biotechnology|December 14, 2011
Dissecting cancer heterogeneityDavid Dornan, Jeff Settleman
Cell|June 21, 2014
From cancer genomics to precision oncology--tissue's still an issueRobert L Cohen, Jeff Settleman
Biochemical Pharmacology|March 10, 2010
Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock"Sreenath V Sharma, Jeff Settleman
Nature|March 9, 2007
Cancer: drivers and passengersDaniel A Haber, Jeff Settleman
Nature Medicine|August 5, 2017
A three-drug combination to treat BRAF-mutant cancersAri J Firestone, Jeff Settleman
Current Genomics|February 3, 2011
Discovering tumor suppressor genes through genome-wide copy number analysisS Michael Rothenberg, Jeff Settleman
Cell|March 12, 2016
Communication in Drug Development: "Translating" Scientific DiscoveryJeff Settleman, Robert L Cohen
Current Opinion in Genetics & Development|February 11, 2012
Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysisRobert L Yauch, Jeff Settleman
Cancer Discovery|April 3, 2021
Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming ResistanceJoachim Rudolph, Jeff Settleman, Shiva Malek
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Cell Cycle (Georgetown, Tex.)|July 1, 2016
TORquing metabolic reprogramming in cancer cellsRaju Pusapati, Jeff Settleman
Nature Biotechnology|December 14, 2011
Dissecting cancer heterogeneityDavid Dornan, Jeff Settleman
Cell|June 21, 2014
From cancer genomics to precision oncology--tissue's still an issueRobert L Cohen, Jeff Settleman
Biochemical Pharmacology|March 10, 2010
Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock"Sreenath V Sharma, Jeff Settleman
Nature|March 9, 2007
Cancer: drivers and passengersDaniel A Haber, Jeff Settleman
Nature Medicine|August 5, 2017
A three-drug combination to treat BRAF-mutant cancersAri J Firestone, Jeff Settleman
Current Genomics|February 3, 2011
Discovering tumor suppressor genes through genome-wide copy number analysisS Michael Rothenberg, Jeff Settleman
Cell|March 12, 2016
Communication in Drug Development: "Translating" Scientific DiscoveryJeff Settleman, Robert L Cohen
Current Opinion in Genetics & Development|February 11, 2012
Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysisRobert L Yauch, Jeff Settleman
Cancer Discovery|April 3, 2021
Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming ResistanceJoachim Rudolph, Jeff Settleman, Shiva Malek
Pageof 7